In other cases, the activation of the PI3K-AKT-mTOR pathway clearly limits the efficacy of G12Ci, such as sotoracide or ARS1620, against NSCLC and PDAC cells [176, 201, 202]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.